because its a clinical supply deal -its VERY early stage development of a novartis drug,so very little money right now attached to deal-all depends how drug does in future development in clinical trials
- mIght be a great deal for UNIS 2-4 years down the road but very limited value right now
It is not just the side effect profile,the main thing isd efficacy-
Whats the use of delivering more drug to tumor site unless there is an efficacy advantage over current standard of care-
EFFICACY FIRST- SAFETY SECONDARY..
IF drugs proves EFFECTIVE and fairly SAFE ,then we have the HOMERUN!
All long investors want,well at least most of them i believe is one,just one more chance to see TTNP go up in share price and make that final exit out of stock-Always nice to make profit on a stock even before product reaches commercialization stages Probuphine,iF ever gets approved I can see value of drug for Braeburn'but not too much for Titan.
Braeburn can sell just 25-50 million yearly of Probuphine for 10 years and profit quite handsomely,
TTNP is left with cheese doodle crumbs on a beer stained couch..
Management can do so much
THe products need to do the talking-You can lead a horse to water but....
Done deals would have been announced by now-its just a wait and see fingers crossed type of situation for shareholders, and even for Alan.NOthing has changed yet-everything is still sketchy here...
The committment is yes for Braeburn to attempt to be profitable on their investment,not Titan
They averaged down by buying more shares.The landscape for opiod addiction treatment might have changed a little,and Probuphines chances of becoming a blockbuster are lessened and Braeburn apparently now realizes this-Not sure how smart they are anyways because if they really expect a long delay for future approval and more trials,share price would surely go down way under their .80 buying price-
Difficult to understand sometimes what others logic is..
Katherine will not be discussing anything at all-she is there to answer a few questions but she will surely not give any voluntary commentaries..
Looks to me like they initially overestimated the worth of Probuphine and now have a different and less revenue model.THey understand the potential is still there for approval but will likely take a long time.
I believe they also think probuphine is worth 50mil a year, not 400 million,based on change in royalty structure.The 5million equity to Titan and owning of 6mil+ shares is countered with the restructure of the FDA approval milestone to Titan, which has dramatically been lowered in Braeburns favor.
I cant see anything real positive for Titan as far as todays announcement other than knowing Braeburn will probably stick around awhile. If there comes a time titan needs any more cash for daily operations,Sunil can devalue Titans piece of Probuphine even more by giving away future royalties or milestones..
ATM is obviously not discounted but this offering will be.
It was already odd when they took the ATM off the table and gave the impression that no dilutive actions will occur near term.Share price then started to run a little but now shockingly' a discounted offering is happening a week later-That is a shareholder unfriendly management move.
titan/braeburn have not filed any appeal and NDA will be many months away from re-submission whenever that occurs, depending on the meeting circumstances-
You starting this rumor kiddo..
The FDA meeting is not an appeal' meeting-it is to discuss the NDA and the CRL and what exactly can be done to get approval the next time....
Maybe some upcoming deals will have nice money attached to them to avoid significant dilution in 2014.
UNIS needs deals that have significant value NOW,not 5-7 years from now
Dilution will run this company to the pits of hell if they cant pay their bills while they wait for some of their products to be commercialized...
JUst go back to their 2 recent deals-
With biodel,they announced its a 110 million dollar dealand with sanofi they announced 5 million cash upfront and potentially 15million in milestones-
This PR has no money attached to deal so this is different from the PR course they have been following-
Deal is probably not financially significant at this time,
Peak sales does not mean first year-anyone looking for 10.00 share price will have to wait a few years if revenues meet estimates Or the easy way to 10.00 if a buyout occurs if this baby gets approved
SEC rules Numbers MUST be disclosed if financially material- IF Alan keeps mum on this than yes it would be smoke and mirrors again.